BPDCN

Data describes BPDCN’s clinical, biological features and patient outcomes
November 12, 2020

A recently published article details the clinical and biological features, and patient outcomes of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematopoietic malignancy.

Venetoclax monotherapy for cutaneous BPDCN
November 11, 2020

B-cell lymphoma-2 inhibitor venetoclax has shown in clinical studies to improve symptoms with minimal toxicity in patients with cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer that can be rapidly fatal without treatment.

CD123-targeted therapies promising in BPDCN and AML
October 06, 2020

Several CD123-targeted therapies have been in development following the FDA’s 2018 approval of tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), but important questions remain when it comes to targeting CD123 in myeloid malignancies.

Tagraxofusp treatment for BPDCN continues to evolve
October 05, 2020

A recent paper details the different ways scientists are investigating tagraxofusp to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy that often presents with skin manifestations.

Tagraxofusp comparable to other chemo regimens as first-line therapy
September 04, 2020

Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.

What dermatologists should know about blastic plasmacytoid dendritic cell neoplasm
September 03, 2020

One expert who is part of a small worldwide group of dedicated scientists and clinicians working to build BPDCN awareness among specialists offers insights from his research for dermatologists.

FDA-approved treatment puts rare cancer with skin manifestations on the map
July 31, 2020

Those who study blastic plasmacytoid dendritic cell neoplasm (BPDCN) struggle to make dermatologists and others aware that the rare hematologic malignancy that often first presents with skin manifestations exists.

Tagraxofusp: efficacy, safety and unanswered questions
July 29, 2020

Tagraxofusp, the first and only FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm (BPDCN), outperforms traditional chemotherapy treatment for the rare myeloid malignancy.

Anti-CD123-CAR T-cell therapy-radiotherapy combo effectively treats recurring blastic plasmacytoid dendritic cell neoplasm
July 14, 2020

The 10-year-old male presented after experiencing five months of bilateral knee joint pain. A bone marrow smear and biopsy revealed the boy had blastic plasmacytoid dendritic cell neoplasm. Doctors treated him and the patient achieved complete remission. The patient presented with a scalp rash one month after his first complete remission.

Review highlights inroads to understanding blastic plasmacytoid dendritic cell neoplasm
July 13, 2020

Studies are revealing clinical, molecular, diagnostic and therapeutic findings that are leading to a better understanding of blastic plasmacytoid dendritic cell neoplasm, and there are promising targeted treatments in the pipeline as well as a growing social media interest.